37115-43-8

Basic information

• Product Name: ALPHA-HYDROXYALPRAZOLAM
• Synonyms: ALPHA-HYDROXYALPRAZOLAM;A-hydroxyalprazolam--dea schedule*iv item;A-HYDROXYALPRAZOLAM;ALPHA-HYDROXYALPRAZOLAM (D5, 98%) 100 UG/ML IN METHANOL;ALPHA-HYDROXYALPRAZOLAM (D5, 98%) 1000 UG/ML IN METHANOL;ALPHA-HYDROXYALPRAZOLAM UNLABELED 1.0 MG/ML IN METHANOL;ALPHA-HYDROXYALPRAZOLAM UNLABELED 100 UG/ML IN METHANOL;4H-1,2,4Triazolo4,3-a1,4benzodiazepine-1-methanol, 8-chloro-6-phenyl-
• CAS NO: 37115-43-8
• Molecular Formula: C₁₇H₁₃ClN₄O
• Molecular Weight: 324.76
• EINECS: 200-659-6
• Product Categories: Intermediates & Fine Chemicals;Metabolites;Pharmaceuticals;Benzodiazepines and Anxiolytics;Neurobiology;Pharmacologicals
• Mol File: 37115-43-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 129-134°C
• Boiling Point: 556.1 °C at 760 mmHg
• Flash Point: 9℃
• Appearance: white to off-white/powder
• Density: 1.45 g/cm³
• Vapor Pressure: 3.34E-13mmHg at 25°C
• Refractive Index: 1.729
• Storage Temp.: -20°C Freezer
• Solubility: methylene chloride: ~20 mg/mL, clear, colorless to faintly
• CAS DataBase Reference: ALPHA-HYDROXYALPRAZOLAM(CAS DataBase Reference)
• NIST Chemistry Reference: ALPHA-HYDROXYALPRAZOLAM(37115-43-8)
• EPA Substance Registry System: ALPHA-HYDROXYALPRAZOLAM(37115-43-8)

Safety Data

• Hazard Codes: Xn,T,F
• Statements: 20/21/22-39/23/24/25-23/24/25-11
• Safety Statements: 36-45-36/37-16-7
• RIDADR: UN1230 - class 3 - PG 2 - Methanol, solution
• WGK Germany: 3
• Hazardous Substances Data: 37115-43-8(Hazardous Substances Data)

Usage

Description

ALPHA-HYDROXYALPRAZOLAM, also known as α-hydroxy Alprazolam, is a major active metabolite of the benzodiazepine alprazolam, commonly sold under the trade name Xanax. It is characterized as a yellow solid and is primarily used as an anxiolytic to treat panic and other anxiety disorders, including generalized or social anxiety disorder. ALPHA-HYDROXYALPRAZOLAM has a lower binding affinity for the GABAA receptor compared to alprazolam and is also a metabolite of adinazolam. ALPHA-HYDROXYALPRAZOLAM is suitable for research and forensic applications, such as forensic analysis, clinical toxicology, urine drug testing, and pain prescription monitoring.

Uses

Used in Pharmaceutical Applications:
ALPHA-HYDROXYALPRAZOLAM is used as an anxiolytic agent for the treatment of panic and anxiety disorders, including generalized or social anxiety disorder. It helps alleviate symptoms by binding to the GABAA receptor, although with a lower affinity than its parent compound, alprazolam.
Used in Forensic Analysis:
ALPHA-HYDROXYALPRAZOLAM is used as an analytical reference material in forensic analysis to identify and quantify the presence of benzodiazepines in biological samples, such as blood or urine.
Used in Clinical Toxicology:
ALPHA-HYDROXYALPRAZOLAM is utilized in clinical toxicology to assess the potential toxic effects of benzodiazepines and their metabolites in patients, particularly in cases of overdose or drug interactions.
Used in Urine Drug Testing:
ALPHA-HYDROXYALPRAZOLAM is employed as a benchmark in urine drug testing to detect the presence of benzodiazepines and monitor their levels in individuals undergoing substance abuse treatment or medication adherence programs.
Used in Pain Prescription Monitoring:
This metabolite is used in pain prescription monitoring to track the use of benzodiazepines in patients with chronic pain, ensuring appropriate prescribing practices and preventing potential misuse or abuse of these medications.

InChI:InChI=1/C17H13ClN4O/c18-12-6-7-14-13(8-12)17(11-4-2-1-3-5-11)19-9-15-20-21-16(10-23)22(14)15/h1-8,23H,9-10H2

Upstream product

• 54042-42-1 N-<<4-(2-Benzoyl-4-chlorophenyl)-5-(hydroxymethyl)-4H-1,2,4-triazol-3-yl>methyl>phthalimide 
• 59010-35-4 1,3-Dioxo-2-isoindolineacetic Acid, <methylene>hydrazine 
• 54485-85-7 N-[4-(2-benzoyl-4-chloro-phenyl)-4H-[1,2,4]triazol-3-ylmethyl]-phthalimide 
• 27610-14-6 3-amino-6-chloro-3,4-dihydro-4-hydroxy-4-phenylquinazoline 
• 37115-40-5 8-chloro-1-(4-methoxy-benzyloxymethyl)-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine 
• 37952-24-2 1-benzhydryloxymethyl-8-chloro-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine 
• 37952-11-7 1-benzyloxymethyl-8-chloro-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine 
• 29975-16-4 estazolam 
• 7789-20-0 water-d2 
• 28981-97-7 alprazolam 

Downstream Products

• 37952-30-0 1-acetoxymethyl-8-chloro-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine 

Relevant articles and documents

Prediction of metabolic clearance using fresh human hepatocytes: Comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines

1. Predictions of in vivo intrinsic clearance from cryopreserved human hepatocytes may be systematically low. In the current study, the metabolite kinetics of a series of CYP3A4 substrates (benzodiazepines) in fresh human hepatocytes from five donors, via a major UK supplier, were investigated and compared with those previously reported (by the authors' laboratory) for cryopreserved human hepatocytes and hepatic microsomes. 2. A high incidence of autoactivation (up to tenfold) and heteroactivation (by testosterone, up to 14-fold) among the major pathways was observed. CYP capacity (Vmax) was marginally lower and 'affinity' constants (KM, S50) were marginally greater compared with cryopreserved hepatocytes. 3. Average intrinsic clearance (based on maximal clearance, CLmax) was sevenfold lower than in cryopreserved hepatocytes (reflecting sensitivity of intrinsic clearance estimation in vitro to mechanistic parameter values, particularly those involving atypical kinetics), but scaled intrinsic clearances for fresh (and cryopreserved) hepatocytes were within the range previously determined in hepatic microsomes. 4. There was no evidence from this series of studies that fresh hepatocytes provide quantitatively improved estimates of intrinsic clearance over cryopreserved hepatocytes.

Triazolobenzodiazepine derivatives

Compounds of the class of 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine-1-lower alkanols, and their ethers and esters, 1-(fluoro-lower alkyl)-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines and the 5-oxides and pharmaceutically acceptable acid addition salts thereof have central depressant properties, in particular antiaggressive and anticonvulsant actions, and are active ingredients for pharmaceutical compositions. Specific embodients are 6-phenyl-8-chloro-4H-s-triazolo[4,3-a][1,4]benzodiazepine-1-methanol and 1-(fluoromethyl)6-phenyl-8-chloro-4H-s-triazolo[4,3-a][1,4]benzodiazepine.

Acetal derivatives of 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine-1-carboxaldehyde

Compounds of the class of acetals of 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine-1-carboxaldehyde and the 5-oxides and pharmaceutically acceptable acid addition salts thereof have valuable pharmacological properties, in particular anticonvulsant effectiveness. Further, they show central depressant and muscle-relaxing activity and are active ingredients for therapeutic preparations. Specific embodiments are 6-phenyl-8-chloro-4H-s-triazolo[4,3-a][1,4]benzodiazepine-1-carboxaldehyde-diethylacetal, 6-(o-chlorophenyl)-8-chloro-4H-s-triazolo[4,3-a][1,4]benzodiazepine-1-carboxaldehyde-diethylacetal and 6-(o-fluorophenyl-8-chloro-4H-s-triazolo[4,3-a][1,4]benzodiazepine-1-carboxaldehyde-diethylacetal.